Nanjing study reveals h. pylori resistance trends in thousands of patients
NCT ID NCT07455448
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 7,227 patients in Nanjing to understand how resistant the H. pylori bacteria is to common antibiotics. The goal was to find out which antibiotics still work best and to help doctors choose the right treatment for each patient. No new treatments were tested; instead, the study gathered information to improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
7,227 people
The number who actually took part.
- Started
-
Mar 2026
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient records were retrieved from the electronic medical record system and laboratory information system of Nanjing First Hospital. The search identified all outpatients who underwent H. pylori culture and genetic testing at the gastroenterology clinic between January 1, 2018, and December 31, 2024, according to pre-defined inclusion and exclusion criteria.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients who visited the Gastroenterology Department of Nanjing First Hospital and underwent gastroscopy with H. pylori culture and genetic testing between 2018 and 2024. 2. Positive for H. pylori by at least one diagnostic method (13C-urea breath test, rapid urease test, or histopathology). 3. Provision of general written informed consent for the use of gastroscopy and specimen data in research. 4. Availability of complete medical records and laboratory test results. Exclusion Criteria: 1. Withdrawal of informed consent; use of antibiotics, proton pump inhibitors, H2-receptor antagonists, or bismuth agents within four weeks prior to gastroscopy. 2. History of gastric surgery. 3. Incomplete medical records or test results precluding evaluation. 4. Other factors deemed by the investigator to render the participant unsuitable for inclusion.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Helicobacter pylori infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing First Hospital
Nanjing, Jiangsu, 210006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stomach biopsies could reveal Antibiotic-Resistant h. pylori without extra tests
- Can a Two-Drug combo beat a stubborn stomach bug?
- A 10-Day h. pylori cure? new trial tests a streamlined approach
- Stomach bug tied to belly fat and blood sugar issues?
- New acid reducer shows promise in fighting stomach bug
- New study tests cheaper h. pylori treatment to beat antibiotic resistance